Siamak Davani
Overview
Explore the profile of Siamak Davani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allemand F, Yesylevskyy S, Lagoutte-Renosi J, Davani S, Ramseyer C
Biochim Biophys Acta Biomembr
. 2024 Nov;
1867(1):184402.
PMID: 39557210
P2Y12 receptors on the platelet plasma membrane are targeted by several antiplatelets drugs. Although oligomerization and functioning of P2Y12 receptors depend on the membrane environment, little is known about their...
2.
Pyrshev K, Allemand F, Rabani V, Yesylevskyy S, Davani S, Ramseyer C, et al.
Br J Pharmacol
. 2024 Jul;
181(21):4369-4380.
PMID: 39014887
Background And Purpose: Although the amphiphilic nature of the widely used antithrombotic drug Ticagrelor is well known, it was never considered as a membranotropic agent capable of interacting with the...
3.
Lagoutte-Renosi J, Karsenty J, Martha B, Davani S, Muret P
AIDS
. 2023 May;
37(7):1181-1183.
PMID: 37139656
No abstract available.
4.
Jacomet C, Lebeller C, Schiestel T, Grandvuillemin A, Davani S, Valnet-Rabier M
Therapie
. 2022 Jun;
77(6):635-647.
PMID: 35643745
Introduction: Pre-exposure prophylaxis (PrEP) is a combination of antiretroviral regimen, tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) that has been shown to prevent HIV transmission. It had been regulated through a temporary...
5.
Tissot M, Valnet-Rabier M, Stalder T, Limat S, Davani S, Nerich V
Therapie
. 2022 Jan;
77(3):291-300.
PMID: 35012757
Aim Of The Study: Serious adverse drug reactions account for 3.6% of French hospital admissions. Of these, 48.5% are, at least potentially, preventable. The first aim of post-marketing pharmacovigilance is...
6.
Lagoutte-Renosi J, Allemand F, Ramseyer C, Yesylevskyy S, Davani S
Drug Discov Today
. 2021 Dec;
27(4):985-1007.
PMID: 34863931
Molecular modeling in pharmacology is a promising emerging tool for exploring drug interactions with cellular components. Recent advances in molecular simulations, big data analysis, and artificial intelligence (AI) have opened...
7.
Lagoutte-Renosi J, Flammang M, Ducloux D, Bamoulid J, Royer P, Lepiller Q, et al.
J Chemother
. 2021 Jun;
34(3):199-202.
PMID: 34180378
We report here a drug-drug interaction with tacrolimus in a HIV-positive patient with renal transplant, after switch from highly active antiretroviral therapy with boosted protease inhibitors to the combination bictegravir/emtricitabine/tenofovir...
8.
Haghighi F, Yesylevskyy S, Davani S, Ramseyer C
Pharmaceutics
. 2021 Apr;
13(4).
PMID: 33918934
The binding of natural ligands and synthetic drugs to the P2Y12 receptor is of great interest because of its crucial role in platelets activation and the therapy of arterial thrombosis....
9.
Lagoutte-Renosi J, Allemand F, Ramseyer C, Rabani V, Davani S
Int J Mol Sci
. 2021 Feb;
22(3).
PMID: 33572690
Lipids contained in the plasma membrane of platelets play an important role in platelet function. Modifications in the lipid composition can fluidify or rigidify the environment around embedded receptors, in...
10.
Lagoutte-Renosi J, Royer B, Rabani V, Davani S
Molecules
. 2021 Jan;
26(2).
PMID: 33429903
Ticagrelor is an antiplatelet agent which is extensively metabolized in an active metabolite: AR-C124910XX. Ticagrelor antagonizes P2Y12 receptors, but recently, this effect on the central nervous system has been linked...